Genentech

Genentech is the founding biotech, and it still trades on that pedigree in every search Recruits Lab runs against it. Candidates who list Genentech on a resume are read as having been trained inside a company that built the modern biologics discovery playbook, from monoclonal antibodies through its long run in oncology, immunology, ophthalmology, and neuroscience.

Roche's ownership has not diluted the brand; it has instead given Genentech access to global development infrastructure while it keeps a distinct South San Francisco R&D culture. Hiring managers looking at Genentech alumni are usually trying to buy scientific rigor and process discipline, not startup speed. The functions growing fastest inside Genentech itself are translational research tied to biomarker-driven trial design, and manufacturing science tied to next-generation biologics modalities.

Genentech runs a matrixed R&D organization split across Research (early discovery), Development (clinical), and gRED versus pRED lineage that predates the Roche integration but still shapes internal culture. Titles worth knowing: Senior Scientist and Principal Scientist in discovery biology and protein engineering, Group Medical Director and Executive Medical Director in clinical development, Director/Senior Director of Regulatory Affairs, and Director of CMC for biologics manufacturing science.

On the commercial side, titles run through Senior Product Manager, Director of Marketing, and Medical Science Liaison into Regional Medical Director. Genentech promotes heavily from within on the medical affairs side, so external candidates often enter at a level below what their years of experience would suggest at a smaller biotech.

Genentech's interview loops are long by industry standards: a recruiter screen, a hiring manager conversation, a technical or scientific presentation to a panel, and then a series of one-on-ones that can stretch the process past six weeks for senior scientific and medical roles. Scientific candidates present original data and defend methodology choices in front of cross-functional panels that include statisticians and clinical pharmacologists.

Culture-fit interviews carry real weight; Genentech has historically self-selected for people who value publication and external scientific credibility alongside internal delivery, which shows up in behavioral questions about collaboration and authorship.

Because Genentech sits inside publicly traded Roche, comp is cash- and RSU-driven rather than pre-IPO equity, which changes the pitch when recruiting toward a private biotech: candidates are trading liquid, low-volatility equity for a bet on the new company's valuation path.

The classic Genentech move is big-pharma-to-biotech-startup: a Senior or Principal Scientist trades a well-resourced lab and a slower approval chain for a smaller team, faster decisions, and equity upside. The best transitions happen when the candidate has already run cross-functional programs internally, not just bench science, because startups need people who can own a program end to end.

Motivators: scientific ownership, faster program timelines, and equity upside after years of RSU-only comp. Blockers: strong internal mobility programs, sabbatical policies, and a genuine sense of mission around the company's oncology and neuroscience pipelines that keeps tenure long in R&D.

Genentech's South San Francisco campus and hybrid policies mean many candidates are open to remote or hybrid roles elsewhere in the Bay Area but resistant to full relocation. Counter-offers from Roche tend to focus on internal transfer opportunities and retention bonuses rather than large base increases; framing the pitch around scientific autonomy and program-level ownership tends to outperform a pure comp argument.